Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma

Hepatology Research

Volumn 44, Issue 2, 2014, Pages 149-158

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Branched chain amino acid granules; Hepatocellular carcinoma; Liver cirrhosis; Liver function; Recurrence

Indexed keywords

BRANCHED CHAIN AMINO ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; SERUM ALBUMIN; SOMATOMEDIN; SORAFENIB; TRYPTOPHAN;

ANTIANGIOGENIC ACTIVITY; CHEMOEMBOLIZATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOALBUMINEMIA; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 84893772606     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12194     Document Type: Review

References (107)

1. Moriwaki H, Miwa Y, Tajika M etal. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004; 313: 405-409.
2. Charlton MR. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006; 136 (1 Suppl): 295S-298.
3. Tajika M, Kato M, Mohri H etal. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002; 18: 229-234.
4. Greco AV, Mingrone G, Benedetti G etal. Daily energy and substrate metabolism in patients with cirrhosis. Hepatology 1998; 27: 346-350.
5. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010; 78: 113-124.
6. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100: 22-29.
7. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
8. de Lope CR, Tremosini S, Forner A etal. Management of HCC. J Hepatol 2012; 56 (Suppl 1): S75-S87.
9. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
10. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
11. Nishikawa H, Osaki Y, Iguchi E etal. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013; 47: 359-366.
12. Zhou WP, Lai EC, Li AJ etal. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009; 249: 195-202.
13. Nishikawa H, Arimoto A, Wakasa T etal. Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol 2013; 42: 151-160.
14. Nishikawa H, Osaki Y, Iguchi E etal. Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma. Anticancer Res 2012; 32: 5059-5065.
15. Nishikawa H, Osaki Y, Kita R etal. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 2012; 41: 903-909.
16. Nishikawa H, Osaki Y, Inuzuka T etal. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2012; 18: 1379-1384.
17. Kawaguchi T, Izumi N, Charlton MR etal. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011; 54: 1063-1070.
18. Muto Y, Sato S, Watanabe A, Moriwaki H etal. Long-Term Survival Study Group. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-713.
19. Moriwaki H, Shiraki M, Fukushima H etal. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res 2008; 38: S102-S106.
20. Hayaishi S, Chung H, Kudo M etal. Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis 2011; 29: 326-332.
21. Yoshiji H, Noguchi R, Kaji K etal. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol 2010; 45: 443-450.
22. Yoshiji H, Noguchi R, Kitade M etal. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009; 44: 483-491.
23. Ohno T, Tanaka Y, Sugauchi F etal. Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. Hepatol Res 2008; 38: 683-688.
24. Nishimura J, Masaki T, Arakawa M etal. Isoleucine prevents the accumulation of tissue triglycerides and upregulates the expression of PPARalpha and uncoupling protein in diet-induced obese mice. J Nutr 2010; 140: 496-500.
25. Kakazu E, Ueno Y, Kondo Y etal. Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 2009; 50: 1936-1945.
26. Nakamura I, Ochiai K, Imai Y etal. Restoration of innate host defense responses by oral supplementation of branched-chain amino acids in decompensated cirrhotic patients. Hepatol Res 2007; 37: 1062-1067.
27. Yoshiji H, Noguchi R, Ikenaka Y etal. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011; 26: 1547-1553.
28. Muto Y, Sato S, Watanabe A etal. for the Long-Term Survival Study (LOTUS) Group. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-214.
29. Ichikawa K, Okabayashi T, Maeda H etal. Oral supplementation of branched-chain amino acids reduces early recurrence after hepatic resection in patients with hepatocellular carcinoma: a prospective study. Surg Today 2013; 43: 720-726.
30. Kumada H, Okanoue T, Onji M etal. Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40 (1): 8-13.
31. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002; 26 (1 Suppl): 1SA-138SA.
32. Plauth M, Cabre E, Riggio O etal. ESPEN Guidelines on Enteral Nutrition: liver disease. Clin Nutr 2006; 25: 285-294.
33. Yatsuhashi H, Ohnishi Y, Nakayama S etal. Anti-hypoalbuminemic effect of branched-chain amino acid granules in patients with liver cirrhosis is independent of dietary energy and protein intake. Hepatol Res 2011; 41: 1027-1035.
34. Fukushima H, Miwa Y, Shiraki M etal. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatol Res 2007; 37: 765-770.
35. Jalan R, Schnurr K, Mookerjee RP etal. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555-564.
36. Takaguchi K, Moriwaki H, Doyama H etal. Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis. Hepatol Res 2013; 43: 459-466.
37. Suzuki K, Endo R, Kohgo Y etal. for the Japanese Nutritional Study Group for Liver Cirrhosis 2008. Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatol Res 2012; 42: 621-626.
38. Habu D, Nishiguchi S, Nakatani S etal. Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. Hepatogastroenterology 2009; 56 (96): 1719-1723.
39. Habu D, Nishiguchi S, Nakatani S etal. Relationship between branched-chain amino acid to tyrosine ratio (BTR) and porto-systemic shunt in the Child-Pugh grade A cirrhosis determined by per-rectal portal scintigraphy. Hepatol Res 2003; 27: 57-61.
40. Shimizu M, Kubota M, Tanaka T etal. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci 2012; 13: 579-595.
41. Kawaguchi T, Nagao Y, Matsuoka H etal. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008; 22: 105-112.
42. Kawamura N, Nakajima H, Takashi SI. Administration of granulated BCAA and quality of life. Hepatol Res 2004; 30S: 42-45.
43. Les I, Doval E, García-Martínez R etal. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 2011; 106: 1081-1088.
44. Marchesini G, Bianchi G, Amodio P etal. Italian Study Group for quality of life in cirrhosis. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-178.
45. Bajaj JS, Saeian K, Schubert CM, Franco R, Franco J, Heuman DM. Disruption of sleep architecture in minimal hepatic encephalopathy and ghrelin secretion. Aliment Pharmacol Ther 2011; 34: 103-105.
46. Saleem DM, Haider S, Khan MM, Shamsi T, Haleem DJ. Role of tryptophan in the pathogenesis of hepatic encephalopathy. J Pak Med Assoc 2008; 58: 68-70.
47. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004; 10 (2 Suppl 1): S46-52.
48. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-1917.
49. Rahbari NN, Mehrabi A, Mollberg NM etal. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453-469.
50. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
51. Kudo M, Izumi N, Kokudo N etal. HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
52. Makuuchi M, Donadon M, Torzilli G. Hepatic resection for hepatocellular carcinoma in cirrhosis. Ann Ital Chir 2008; 79: 111-115.
53. Ikai I, Arii S, Okazaki M etal. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
54. Horino K, Beppu T, Kuroki H etal. Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol 2012 Jul 21. [Epub ahead of print].
55. Takuma Y, Nouso K, Makino Y etal. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol 2011; 26: 1417-1424.
56. Ikai I, Arii S, Kojiro M etal. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
57. Chang WT, Kao WY, Chau GY etal. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery 2012; 152: 809-820.
58. Togo S, Tanaka K, Morioka D etal. Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis. Nutrition 2005; 21: 480-486.
59. [No authors listed] Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg 1997; 84: 1525-1531.
60. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
61. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (1): e11-22.
62. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012; 56: 1983-1992.
63. Sugawara Y, Makuuchi M. Living donor liver transplantation: present status and recent advances. Br Med Bull 2006; 75-76: 15-28.
64. Sugawara Y, Makuuchi M. Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. Liver Transpl 2004; 10: 715-720.
65. Kawamura E, Habu D, Morikawa H etal. A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status. Liver Transpl 2009; 15: 790-797.
66. Shirabe K, Yoshimatsu M, Motomura T etal. Beneficial effects of supplementation with branched-chain amino acids on postoperative bacteremia in living donor liver transplant recipients. Liver Transpl 2011; 17: 1073-1080.
67. Nishikawa H, Osaki Y, Iguchi E etal. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2012 Oct 12. [Epub ahead of print].
68. Nishikawa H, Inuzuka T, Takeda H etal. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 2011; 46: 1418-1426.
69. Shiina S, Tateishi R, Arano T etal. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-577.
70. Tateishi R, Shiina S, Teratani T etal. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-1209.
71. Nishikawa H, Osaki Y, Iguchi E etal. Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Gastrointestin Liver Dis 2012; 21: 397-405.
72. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011; 98: 1210-1224.
73. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116: 5452-5460.
74. Li JX, Wu H, Huang JW, Zeng Y. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formos Med Assoc 2012; 111: 510-515.
75. Kuroda H, Ushio A, Miyamoto Y etal. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010; 25: 1550-1555.
76. Morihara D, Iwata K, Hanano T etal. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2012; 42: 658-667.
77. Shimomura S, Ikeda N, Saito M etal. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 2010; 5: 559-566.
78. Kudo M, Sakaguchi Y, Chung H etal. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007; 72 (Suppl 1): 132-138.
79. Xia F, Lai EC, Lau WY etal. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 1284-1291.
80. Goto T, Yoshida H, Tateishi R etal. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int 2011; 5: 767-773.
81. Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis 2002; 23: 885-892.
82. Chung GE, Yoon JH, Lee JH etal. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncol Rep 2011; 25: 1739-1746.
83. Chen CJ, Yang HI, Su J etal. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
84. Takayasu K, Arii S, Ikai I etal. Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
85. Matsui O. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. Clin Drug Investig 2012; 32 (Suppl 2): 3-13.
86. Matsui O, Miyayama S, Sanada J etal. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci 2010; 17: 407-409.
87. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401.
88. Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol 2012; 42: 247-255.
89. Takayasu K, Arii S, Kudo M etal. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886-892.
90. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68: 2150-2154.
91. Takeshita S, Ichikawa T, Nakao K etal. A snack with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res 2009; 29: 89-93.
92. Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 2004; 19: 779-788.
93. Pomoni M, Malagari K, Moschouris H etal. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 2012; 59 (115): 820-825.
94. Koreeda C, Seki T, Okazaki K, Ha-Kawa SK, Sawada S. Effects of late evening snack including branched-chain amino acid on the function of hepatic parenchymal cells in patients with liver cirrhosis. Hepatol Res 2011; 41: 417-422.
95. Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers 2012; 4: 165-183.
96. Llovet JM, Ricci S, Mazzaferro V etal. SHARP Investigators Study Group: sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
97. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
98. Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
99. Baek KK, Kim JH, Uhm JE etal. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011; 80: 167-174.
100. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J, on behalf of the SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-2300.
101. Takeda H, Nishikawa H, Iguchi E etal. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clin J Gastroenterol 2012; 5: 407-412.
102. Takeda H, Nishikawa H, Iguchi E etal. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol 2013; 1: 241-248.
103. Nishikawa H, Osaki Y, Iguchi E etal. Comparison of the efficacy of transcatheter arterialchemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012; 4: 381-386.
104. Kudo M, Tateishi R, Yamashita T etal. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig 2012; 32 (Suppl 2): 37-51.
105. Kudo M, Ueshima K, Arizumi T. Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. Dig Dis 2012; 30: 609-616.
106. Inuzuka T, Nishikawa H, Sekikawa A etal. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology 2011; 81 (Suppl 1): 152-157.
107. Takeda H, Nishikawa H, Iguchi E etal. Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma. Hepatol Res 2013. doi: 10.1111/hepr.12125